Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
British Journal of Haematology|August 15, 2019
A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United KingdomFaye A Sharpley, Aviva Petrie, Shameem Mahmood, et al.
British Journal of Haematology|February 21, 2025
Outcomes of daratumumab-bortezomib-thalidomide-dexamethasone in treatment-naive systemic AL amyloidosisJahanzaib Khwaja, Sriram Ravichandran, Oliver Cohen, et al.
European Journal of Haematology|June 5, 2020
The value of screening biopsies in light-chain (AL) and transthyretin (ATTR) amyloidosisOliver C Cohen, Faye Sharpley, Janet A Gilbertson, et al.
British Journal of Haematology|June 30, 2021
Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal dataSriram Ravichandran, Oliver C Cohen, Steven Law, et al.
Blood Cancer Journal|June 22, 2021
Impact of early response on outcomes in AL amyloidosis following treatment with frontline BortezomibSriram Ravichandran, Oliver C Cohen, Steven Law, et al.
British Journal of Haematology|May 5, 2022
A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosisSriram Ravichandran, Shameem Mahmood, Brenden Wisniowski, et al.
British Journal of Haematology|June 6, 2024
Response rates to second-line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain amyloidosis (AL) after initial Bortezomib-based regimeJoshua Bomsztyk, Sriram Ravichandran, Jahanzaib Khwaja, et al.
British Journal of Haematology|June 17, 2014
Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimensShameem Mahmood, Christopher P Venner, Sajitha Sachchithanantham, et al.
European Journal of Haematology|January 18, 2021
Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first-line treatment of systemic light chain amyloidosis in the UKFaye A Sharpley, Richa Manwani, Aviva Petrie, et al.
Kidney International|July 22, 2017
Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factorTamer Rezk, Helen J Lachmann, Marianna Fontana, et al.
Pageof 6